Investigational drug · Phase 2
NGGT001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Bietti Crystalline Corneoretinal Dystrophy.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "NGGT001"
First trial start
2024
Mar 21, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NGGT001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Bietti Crystalline Corneoretinal Dystrophy
Approved drugs for the same conditions: Rare and genetic disease · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "NGGT001" as an intervention, largest first.
- Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy SubjectsActive, not recruiting
NGGT (Suzhou) Biotechnology Co., Ltd.Industry
NCT06706427 · 12 participants · Start Mar 21, 2024 · Primary completion Nov 30, 2025
Drug: NGGT001 · For: Bietti Crystalline Corneoretinal Dystrophy
Sites: Chongqing, China; Xiamen, China
Newest research
PubMed records naming it or its code names, newest first.
- Phase I/II Study of NGGT001 Gene Therapy for Bietti Crystalline Dystrophy.
Chen X, Yang L, Wang G, et al. · Ophthalmol Sci 2026
- Bietti crystalline corneoretinal dystrophy: Advances in understanding and gene therapeutic approaches.
Zhao G, Ding D · Mol Vis 2025
- Safety and Vision Outcomes Following Gene Therapy for Bietti Crystalline Dystrophy: A Nonrandomized Clinical Trial.
Chen X, Liu X, Cui S, et al. · JAMA Ophthalmol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.